PMID- 32865914
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200909
IS  - 2162-6537 (Electronic)
IS  - 0731-8898 (Linking)
VI  - 39
IP  - 3
DP  - 2020
TI  - Effects of Boldine on Antioxidants and Allied Inflammatory Markers in Mouse 
      Models of Asthma.
PG  - 225-234
LID - 10.1615/JEnvironPatholToxicolOncol.2020034039 [doi]
AB  - Asthma is marked by chronic irritation in the airway lumen of the lungs due to 
      the accretion of inflammatory cells that influence the regular inhalation 
      process. An extended buildup of inflammation leads to oxidative pressure and the 
      repression of antioxidant functions. In the current study, a potential compound, 
      boldine, was tested for the containment of provocative markers along the path of 
      antiasthmatic activity in an ovalbumin (OVA)-induced asthmatic mice model. As an 
      effect, the boldine (10 and 20 mg/kg) treatment suppressed inflammatory cells 
      such as eosinophil, macrophage, neutrophil, lymphocyte, and other inflammatory 
      markers in the bronchoalveolar lavage fluid (BALF) of OVA-induced mice. Likewise, 
      immunoglobulin E (IgE) levels were drastically condensed in the serum of 
      boldine-treated animals. Levels of enzymatic and nonenzymatic antioxidants, such 
      as superoxide dismutase (SOD) and glutathione (GSH), were upregulated in the 
      boldine treatment group compared to the asthmatic control group, which displays 
      the antioxidant effects of boldine on asthmatic animals. Interestingly, the 
      reactive oxygen species (ROS) and malonaldehyde (MDA) levels were repressed in 
      the BALF of boldine-treated mice groups. Therefore, the effects of boldine are 
      significant for the management of asthma, reducing the accrual of inflammatory 
      cells, along with other inflammatory markers, while improving antioxidant markers 
      and containing ROS. Hence, boldine may be an option for clinical trials of 
      chronic asthma management.
FAU - Li, Wei
AU  - Li W
AD  - Department of Pediatrics, Shanghai General Hospital, Shanghai, China.
FAU - Veeraraghavan, Vishnu Priya
AU  - Veeraraghavan VP
AD  - Department of Biochemistry, Saveetha Dental College, Saveetha Institute of 
      Medical and Technical Sciences, Saveetha University, Chennai, 600 077, India.
FAU - Ma, Weining
AU  - Ma W
AD  - Department of Pediatrics, Shanghai General Hospital, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Environ Pathol Toxicol Oncol
JT  - Journal of environmental pathology, toxicology and oncology : official organ of 
      the International Society for Environmental Toxicology and Cancer
JID - 8501420
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Aporphines)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Reactive Oxygen Species)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 8I91GE2769 (boldine)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/administration & dosage/*therapeutic use
MH  - Anti-Inflammatory Agents/administration & dosage/*therapeutic use
MH  - Antioxidants/*metabolism
MH  - Aporphines/administration & dosage/*therapeutic use
MH  - Asthma/*drug therapy/immunology
MH  - Biomarkers/analysis
MH  - Bronchoalveolar Lavage Fluid/chemistry/cytology/immunology
MH  - Cytokines/analysis
MH  - Disease Models, Animal
MH  - Eosinophils/cytology
MH  - Immunoglobulin E/blood
MH  - Lung/drug effects/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Ovalbumin/immunology
MH  - Reactive Oxygen Species/metabolism
MH  - Respiratory Function Tests
EDAT- 2020/09/01 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - 6cc205ba6c85dd8d,785998b43e9e14b2 [pii]
AID - 10.1615/JEnvironPatholToxicolOncol.2020034039 [doi]
PST - ppublish
SO  - J Environ Pathol Toxicol Oncol. 2020;39(3):225-234. doi: 
      10.1615/JEnvironPatholToxicolOncol.2020034039.